Eberlein C, Williamson SC, Hopcroft L, Ros S, et al. Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer. Br J Cancer 2024 Feb 23. doi: 10.1038/s41416-024-02614.
PMID: 38396173